Product Code: ETC13203774 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Cell And Gene Therapy CDMO Market was valued at USD 5.8 Billion in 2024 and is expected to reach USD 12.5 Billion by 2031, growing at a compound annual growth rate of 8.80% during the forecast period (2025-2031).
The Global Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is experiencing rapid growth due to the increasing demand for personalized and targeted therapies. CDMOs play a crucial role in providing specialized manufacturing and development services to biotechnology and pharmaceutical companies in the cell and gene therapy space. Factors such as technological advancements, favorable regulatory environment, and the rising investment in research and development activities are driving the market expansion. Key players in the market are focusing on expanding their capabilities, enhancing manufacturing efficiency, and establishing strategic partnerships to meet the growing demand for cell and gene therapy products. The market is expected to continue its upward trajectory in the coming years as more innovative therapies enter the market and the adoption of these advanced treatments increases globally.
The Global Cell and Gene Therapy CDMO market is witnessing rapid growth due to the increasing demand for personalized medicine and advancements in biotechnology. Key trends include the rise of outsourcing services to CDMOs by biopharmaceutical companies to leverage specialized expertise and infrastructure, as well as the growing number of collaborations and partnerships between CDMOs and pharmaceutical companies to accelerate product development. Additionally, the market is seeing a shift towards more automated and streamlined manufacturing processes to enhance efficiency and reduce costs. Opportunities in this market include expanding into emerging markets, such as Asia-Pacific, to capitalize on the growing demand for cell and gene therapy products, as well as investing in innovative technologies to meet the evolving needs of the industry.
The Global Cell and Gene Therapy CDMO market faces several challenges, including the high cost of manufacturing these therapies due to complex processes and specialized facilities required. There is also a shortage of skilled personnel with expertise in cell and gene therapy manufacturing, leading to capacity constraints and delays in production. Additionally, regulatory uncertainty and evolving guidelines pose challenges for CDMOs in ensuring compliance and adapting quickly to changing requirements. Another key challenge is the need for robust supply chain management to ensure the timely delivery of materials and components for manufacturing these advanced therapies. Overall, navigating these challenges requires strategic planning, investment in infrastructure and technology, as well as strong partnerships to drive innovation and growth in the Cell and Gene Therapy CDMO market.
The Global Cell and Gene Therapy CDMO (Contract Development and Manufacturing Organization) market is primarily driven by the increasing demand for personalized medicine and advanced therapies, the growing pipeline of cell and gene therapy products, and the complexity of manufacturing these innovative treatments. Additionally, the expansion of biopharmaceutical companies into cell and gene therapy, coupled with the need for specialized expertise and infrastructure for manufacturing, is fueling the demand for CDMOs. Furthermore, regulatory support and initiatives to expedite the development and commercialization of cell and gene therapies are also contributing to the market growth. The focus on scalability, cost-efficiency, and quality in manufacturing processes to meet the rising demand for cell and gene therapies is driving biopharmaceutical companies to partner with CDMOs for their expertise and resources.
Government policies related to the Global Cell and Gene Therapy CDMO market play a significant role in shaping the industry landscape. Regulatory bodies such as the FDA in the US and the EMA in Europe have established guidelines to ensure the safety, quality, and efficacy of cell and gene therapy products. These regulations cover various aspects including manufacturing practices, clinical trials, and marketing authorization. Additionally, governments may offer incentives such as tax credits, grants, and expedited review processes to promote the development and commercialization of cell and gene therapies. Overall, government policies aim to facilitate innovation, streamline regulatory processes, and foster a conducive environment for the growth of the Cell and Gene Therapy CDMO market on a global scale.
The Global Cell And Gene Therapy CDMO Market is expected to experience significant growth in the coming years as the demand for personalized medicine and advanced therapies continues to rise. The increasing prevalence of chronic diseases, coupled with advancements in biotechnology and genetic engineering, will drive the market expansion. Additionally, the outsourcing of manufacturing processes to Contract Development and Manufacturing Organizations (CDMOs) will become more prevalent as companies seek to streamline operations and reduce costs. As a result, the Global Cell And Gene Therapy CDMO Market is projected to witness robust growth, with key players investing in expanding their capabilities and capacity to meet the growing demand for these innovative therapies globally.
The Global Cell and Gene Therapy CDMO market shows promising growth prospects across various regions. In Asia, the market is driven by the presence of a large population base, increasing investments in healthcare infrastructure, and growing collaborations between research institutions and CDMOs. North America leads the market due to a well-established healthcare system, supportive regulatory environment, and high adoption of advanced therapies. In Europe, the market is propelled by strong R&D activities, government initiatives promoting cell and gene therapy, and increasing partnerships between CDMOs and pharmaceutical companies. The Middle East and Africa region is witnessing gradual growth with rising awareness about advanced therapies and improving healthcare infrastructure. Latin America is also emerging as a key market with growing investments in biotechnology and increasing focus on personalized medicine.
Global Cell And Gene Therapy CDMO Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Cell And Gene Therapy CDMO Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Global Cell And Gene Therapy CDMO Market - Industry Life Cycle |
3.4 Global Cell And Gene Therapy CDMO Market - Porter's Five Forces |
3.5 Global Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Phase, 2021 & 2031F |
3.7 Global Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.8 Global Cell And Gene Therapy CDMO Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Global Cell And Gene Therapy CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Cell And Gene Therapy CDMO Market Trends |
6 Global Cell And Gene Therapy CDMO Market, 2021 - 2031 |
6.1 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Pre-clinical, 2021 - 2031 |
6.1.3 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Clinical, 2021 - 2031 |
6.2 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Gene Therapy, 2021 - 2031 |
6.2.3 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Gene-Modified Cell Therapy, 2021 - 2031 |
6.2.4 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Cell Therapy, 2021 - 2031 |
6.3 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Oncology, 2021 - 2031 |
6.3.3 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Infectious Diseases, 2021 - 2031 |
6.3.4 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Neurological disorders, 2021 - 2031 |
6.3.5 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Rare Diseases, 2021 - 2031 |
6.3.6 Global Cell And Gene Therapy CDMO Market, Revenues & Volume, By Others, 2021 - 2031 |
7 North America Cell And Gene Therapy CDMO Market, Overview & Analysis |
7.1 North America Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
7.2 North America Cell And Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
7.4 North America Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
7.5 North America Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
8 Latin America (LATAM) Cell And Gene Therapy CDMO Market, Overview & Analysis |
8.1 Latin America (LATAM) Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Cell And Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
8.4 Latin America (LATAM) Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
8.5 Latin America (LATAM) Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
9 Asia Cell And Gene Therapy CDMO Market, Overview & Analysis |
9.1 Asia Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Cell And Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
9.4 Asia Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
9.5 Asia Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
10 Africa Cell And Gene Therapy CDMO Market, Overview & Analysis |
10.1 Africa Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Cell And Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
10.4 Africa Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
10.5 Africa Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
11 Europe Cell And Gene Therapy CDMO Market, Overview & Analysis |
11.1 Europe Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Cell And Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
11.4 Europe Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
11.5 Europe Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
12 Middle East Cell And Gene Therapy CDMO Market, Overview & Analysis |
12.1 Middle East Cell And Gene Therapy CDMO Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Cell And Gene Therapy CDMO Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Cell And Gene Therapy CDMO Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Cell And Gene Therapy CDMO Market, Revenues & Volume, By Phase, 2021 - 2031 |
12.4 Middle East Cell And Gene Therapy CDMO Market, Revenues & Volume, By Product Type, 2021 - 2031 |
12.5 Middle East Cell And Gene Therapy CDMO Market, Revenues & Volume, By Indication, 2021 - 2031 |
13 Global Cell And Gene Therapy CDMO Market Key Performance Indicators |
14 Global Cell And Gene Therapy CDMO Market - Export/Import By Countries Assessment |
15 Global Cell And Gene Therapy CDMO Market - Opportunity Assessment |
15.1 Global Cell And Gene Therapy CDMO Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Cell And Gene Therapy CDMO Market Opportunity Assessment, By Phase, 2021 & 2031F |
15.3 Global Cell And Gene Therapy CDMO Market Opportunity Assessment, By Product Type, 2021 & 2031F |
15.4 Global Cell And Gene Therapy CDMO Market Opportunity Assessment, By Indication, 2021 & 2031F |
16 Global Cell And Gene Therapy CDMO Market - Competitive Landscape |
16.1 Global Cell And Gene Therapy CDMO Market Revenue Share, By Companies, 2024 |
16.2 Global Cell And Gene Therapy CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |